NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing…
Interim Data Analysis Anticipated in Mid-2024Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics,…
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio Manager,…
Figure 1 Atacicept 72-week Data From the Phase 2b ORIGIN Trial Are Consistent With a Profile of True Disease Modification…
TURKU, Finland and BOSTON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage…
Press Release Nicox Provides Fourth Quarter 2023 Financial and Business Highlights NCX 470 Phase 3 Denali clinical trial 75% randomizedNet…
PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World…
GOTHENBURG, SWEDEN / ACCESSWIRE / January 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2023 (October 1 - December 31)…
NMQF Releases Report that 56% of People of Color Live in Carcinogenic Environments; Announce Public-Private Collaboration to Address ProblemWashington, D.C.--(Newsfile…
GOTHENBURG, SE / ACCESSWIRE / January 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) In a recently published [1] clinical…